Defymed® is a company that aims to develop and market implantable bio-artificial medical devices for diverse therapeutic applications.
Defymed® is a company that develops implantable bio-artificial medical devices for diverse therapeutic applications, with a first focus on type 1 diabetes. The blockbuster product is a bio-artificial pancreas, named MAILPAN® (MAcro-encapsulation of PANcreatic Islets). Defymed® is a spin-off of the CeeD (Centre europeen d’etude du Diabete) which has been working on an innovative concept of a bio-artificial pancreas since 1996. This work of conception of a macro-encapsulation device of insulin-secretory cells was carried out in collaboration with STATICE and the CTTM (Centre de Transfert de Technologies du Mans) in the frame of two European programs: 4th PCRD (1996-2000) and 6th PCRD (2004-2007).
